[{"id":"22d4974b-1f87-4110-84a2-c0649aaebd18","acronym":"","url":"https://clinicaltrials.gov/study/NCT04860817","created_at":"2021-04-27T14:52:26.939Z","updated_at":"2024-07-02T16:35:59.865Z","phase":"Phase 1","brief_title":"A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL","source_id_and_acronym":"NCT04860817","lead_sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • GC027"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2022-11-29"},{"id":"3c221147-01f9-418b-94a7-e250636cdc68","acronym":"","url":"https://clinicaltrials.gov/study/NCT04264078","created_at":"2021-01-18T20:43:26.538Z","updated_at":"2025-02-25T14:58:53.459Z","phase":"Phase 1","brief_title":"Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies","source_id_and_acronym":"NCT04264078","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • GC027 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2021-06-28"}]